Acalabrutinib

Therapeutic indications

Acalabrutinib is indicated for:

Mantle cell lymphoma (MCL)

Population group: both men and women, only adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Chronic lymphocytic leukaemia (CLL)

Population group: both men and women, only adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Small lymphocytic lymphoma (SLL)

Population group: both men and women, only adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with small lymphocytic lymphoma (SLL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines